CTC enumeration and characterization as a pharmacodynamic marker in the phase I clinical study of APX3330, an APE1/Ref-1 inhibitor, in patients with advanced solid tumors.

Lincy Chu,Amanda K. L. Anderson,Mark Landers,Yipeng Wang,Mark R. Kelley,Richard A. Messmann

CTC enumeration and characterization as a pharmacodynamic marker in the phase I clinical study of APX3330, an APE1/Ref-1 inhibitor, in patients with advanced solid tumors.

2019

Lincy Chu
Amanda K. L. Anderson
Mark Landers
Yipeng Wang
Mark R. Kelley
Richard A. Messmann

e14531Background: APE1/Ref-1 is a dual-function protein with a pleiotropic role in regulating transcription factors involved in cancer cell signaling via redox control, as well as responding to oxi...

Keywords:

Pharmacodynamics
Enumeration
Oncology
Pathology
Medicine
Internal medicine
in patient
Cancer research
Cancer cell
ape1 ref 1
clinical study
Transcription factor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations